A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma
- Assess the antitumor activity of pyrazoloacridine (PZA) in chemotherapy naive patients
with metastatic cutaneous or ocular melanoma.
- Determine the toxic effects of PZA in this patient population.
- Determine the pharmacokinetic profile of PZA in these patients.
OUTLINE: Patients are stratified into cutaneous or ocular melanoma treatment groups.
Patients receive pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 21
days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: Approximately 28-70 patients will be accrued for this study.
Primary Purpose: Treatment
William H. Sharfman, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|